Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.71 |
| ▸ | HTR2A | P28223 | 13/20 | 0.70 |
| ▸ | DRD3 | P35462 | 13/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249919 | 1.00 | ACHE (0.71) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL15859552 | 0.92 | HTR2A (0.70) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL605223 | 0.92 | HTR2A (0.70) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL607419 | 0.91 | HTR2A (0.69) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL607420 | 0.91 | HTR2A (0.69) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL28504239 | 0.89 | ACHE (0.71) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL605707 | 0.87 | HTR2A (0.70) | HTR2ADRD3 | |
| SCHEMBL3249824 | 0.87 | HTR2A (0.70) | HTR2ADRD3 | |
| SCHEMBL604059 | 0.87 | HTR2A (0.73) | ACHEHTR2ADRD3DRD2SLC6A4 | |
| SCHEMBL606612 | 0.87 | HTR2A (0.73) | ACHEHTR2ADRD3DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HOFFMAN-LA ROCHE INC. | 2014-11-27 | — | — | US | claimed |
| US-8829029-B2 | Dual modulators of 5HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | claimed |
| EP-2183245-B1 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-07-09 | — | — | EP | claimed |
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-06-27 | — | — | US | claimed |
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-02-16 | — | — | US | claimed |
| EP-2183245-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | claimed |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | claimed |
| WO-2009013212-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | claimed |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HOFFMAN-LA ROCHE INC. | 2014-11-27 | — | — | US | disclosed |
| US-8829029-B2 | Dual modulators of 5HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2183245-B1 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-02-16 | — | — | US | disclosed |
| EP-2183245-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013212-A2 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165432-A1 | Dual Modulators of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | ACHE 682/4885HTR2A 1/4885DRD3 10/4885 |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | ACHE 682/4885HTR2A 1/4885DRD3 10/4885 |
| US-20120040972-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | ACHE 682/4885HTR2A 1/4885DRD3 10/4885 |
| US-20090029977-A1 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR1A | ACHE 682/4885HTR2A 1/4885DRD3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.